Proton linear energy transfer and variable relative biological effectiveness for adolescent patients with Hodgkin lymphoma.

Objectives: Proton therapy has a theoretical dosimetric advantage due to the Bragg peak, but the linear energy transfer (LET), and therefore the relative biological effectiveness (RBE), increase at the end of range. For patients with Hodgkin lymphoma, the distal edge of beam is often located within or close to the heart, where elevated RBE would be of potential concern. The purpose of this study was to investigate the impact of RBE and the choice of beam arrangement for adolescent patients with mediastinal Hodgkin lymphoma. Methods: For three previously treated adolescent patients, proton plans with 1-3 fields were created to a prescribed dose of 19.8 Gy (RBE) in 11 fractions (Varian Eclipse v13.7), assuming an RBE of 1.1. Plans were recalculated using Monte-Carlo (Geant4 v10.3.3/Gate v8.1) to calculate dose-averaged LET. Variable RBE-weighted dose was calculated using the McNamara model, assuming an α/ß ratio of 2 Gy for organs-at-risk. Results: Although the LET decreased as the number of fields increased, the difference in RBE-weighted dose (Δdose) to organs-at-risk did not consistently decrease. Δdose values varied by patient and organ and were mostly of the order of 0-3 Gy (RBE), with a worst-case of 4.75 Gy (RBE) in near-maximum dose to the left atrium for one plan. Conclusions: RBE-weighted doses to organs-at-risk are sensitive to the choice of RBE model, which is of particular concern for the heart. Advances in knowledge: There is a need to remain cautious when evaluating proton plans for Hodgkin lymphoma, especially when near-maximum doses to organs-at-risk are considered.

Proposing a Clinical Model for RBE Based on Proton Track-End Counts.

PURPOSE: In proton therapy, the clinical application of linear energy transfer (LET) optimization remains contentious, in part because of challenges associated with the definition and calculation of LET and its exact relationship with relative biological effectiveness (RBE) because of large variation in experimental in vitro data. This has raised interest in other metrics with favorable properties for biological optimization, such as the number of proton track ends in a voxel. In this work, we propose a novel model for clinical calculations of RBE, based on proton track end counts. METHODS AND MATERIALS: We developed an effective dose concept to translate between the total proton track-end count per unit mass in a voxel and a proton RBE value. Dose, track end, and dose-averaged LET (LETd) distributions were simulated using Monte Carlo models for a series of water phantoms, in vitro radiobiological studies, and patient treatment plans. We evaluated the correlation between track ends and regions of elevated biological effectiveness in comparison to LETd-based models of RBE. RESULTS: Track ends were found to correlate with biological effects in in vitro experiments with an accuracy comparable to LETd. In patient simulations, our track end model identified the same biological hotspots as predicted by LETd-based radiobiological models of proton RBE. CONCLUSIONS: These results suggest that, for clinical optimization and evaluation, an RBE model based on proton track end counts may match LETd-based models in terms of information provided while also offering superior statistical properties.

A preclinical radiotherapy dosimetry audit using a realistic 3D printed murine phantom.

Preclinical radiation research lacks standardized dosimetry procedures that provide traceability to a primary standard. Consequently, ensuring accuracy and reproducibility between studies is challenging. Using 3D printed murine phantoms we undertook a dosimetry audit of Xstrahl Small Animal Radiation Research Platforms (SARRPs) installed at 7 UK centres. The geometrically realistic phantom accommodated alanine pellets and Gafchromic EBT3 film for simultaneous measurement of the dose delivered and the dose distribution within a 2D plane, respectively. Two irradiation scenarios were developed: (1) a 10 × 10 mm2 static field targeting the pelvis, and (2) a 5 × 5 mm2 90° arc targeting the brain. For static fields, the absolute difference between the planned dose and alanine measurement across all centres was 4.1 ± 4.3% (mean ± standard deviation), with an overall range of - 2.3 to 10.5%. For arc fields, the difference was - 1.2% ± 6.1%, with a range of - 13.1 to 7.7%. EBT3 dose measurements were greater than alanine by 2.0 ± 2.5% and 3.5 ± 6.0% (mean ± standard deviation) for the static and arc fields, respectively. 2D dose distributions showed discrepancies to the planned dose at the field edges. The audit demonstrates that further work on preclinical radiotherapy quality assurance processes is merited.

Estimating the percentage of patients who might benefit from proton beam therapy instead of X-ray radiotherapy.

OBJECTIVES: High-energy Proton Beam Therapy (PBT) commenced in England in 2018 and NHS England commissions PBT for 1.5% of patients receiving radical radiotherapy. We sought expert opinion on the level of provision. METHODS: Invitations were sent to 41 colleagues working in PBT, most at one UK centre, to contribute by completing a spreadsheet. 39 responded: 23 (59%) completed the spreadsheet; 16 (41%) declined, arguing that clinical outcome data are lacking, but joined six additional site-specialist oncologists for two consensus meetings. The spreadsheet was pre-populated with incidence data from Cancer Research UK and radiotherapy use data from the National Cancer Registration and Analysis Service. 'Mechanisms of Benefit' of reduced growth impairment, reduced toxicity, dose escalation and reduced second cancer risk were examined. RESULTS: The most reliable figure for percentage of radical radiotherapy patients likely to benefit from PBT was that agreed by 95% of the 23 respondents at 4.3%, slightly larger than current provision. The median was 15% (range 4-92%) and consensus median 13%. The biggest estimated potential benefit was from reducing toxicity, median benefit to 15% (range 4-92%), followed by dose escalation median 3% (range 0 to 47%); consensus values were 12 and 3%. Reduced growth impairment and reduced second cancer risk were calculated to benefit 0.5% and 0.1%. CONCLUSIONS: The most secure estimate of percentage benefit was 4.3% but insufficient clinical outcome data exist for confident estimates. The study supports the NHS approach of using the evidence base and developing it through randomised trials, non-randomised studies and outcomes tracking. ADVANCES IN KNOWLEDGE: Less is known about the percentage of patients who may benefit from PBT than is generally acknowledged. Expert opinion varies widely. Insufficient clinical outcome data exist to provide robust estimates. Considerable further work is needed to address this, including international collaboration; much is already underway but will take time to provide mature data.

Towards harmonizing clinical linear energy transfer (LET) reporting in proton radiotherapy: a European multi-centric study.

BACKGROUND: Clinical data suggest that the relative biological effectiveness (RBE) in proton therapy (PT) varies with linear energy transfer (LET). However, LET calculations are neither standardized nor available in clinical routine. Here, the status of LET calculations among European PT institutions and their comparability are assessed. MATERIALS AND METHODS: Eight European PT institutions used suitable treatment planning systems with their center-specific beam model to create treatment plans in a water phantom covering different field arrangements and fulfilling commonly agreed dose objectives. They employed their locally established LET simulation environments and procedures to determine the corresponding LET distributions. Dose distributions D1.1 and DRBE assuming constant and variable RBE, respectively, and LET were compared among the institutions. Inter-center variability was assessed based on dose- and LET-volume-histogram parameters. RESULTS: Treatment plans from six institutions fulfilled all clinical goals and were eligible for common analysis. D1.1 distributions in the target volume were comparable among PT institutions. However, corresponding LET values varied substantially between institutions for all field arrangements, primarily due to differences in LET averaging technique and considered secondary particle spectra. Consequently, DRBE using non-harmonized LET calculations increased inter-center dose variations substantially compared to D1.1 and significantly in mean dose to the target volume of perpendicular and opposing field arrangements (p < 0.05). Harmonizing LET reporting (dose-averaging, all protons, LET to water or to unit density tissue) reduced the inter-center variability in LET to the order of 10-15% within and outside the target volume for all beam arrangements. Consequentially, inter-institutional variability in DRBE decreased to that observed for D1.1. CONCLUSION: Harmonizing the reported LET among PT centers is feasible and allows for consistent multi-centric analysis and reporting of tumor control and toxicity in view of a variable RBE. It may serve as basis for harmonized variable RBE dose prescription in PT.

A Monte Carlo study of different LET definitions and calculation parameters for proton beam therapy.

The strongin vitroevidence that proton Relative Biological Effectiveness (RBE) varies with Linear Energy Transfer (LET) has led to an interest in applying LET within treatment planning. However, there is a lack of consensus on LET definition, Monte Carlo (MC) parameters or clinical methodology. This work aims to investigate how common variations of LET definition may affect potential clinical applications. MC simulations (GATE/GEANT4) were used to calculate absorbed dose and different types of LET for a simple Spread Out Bragg Peak (SOBP) and for four clinical PBT plans covering a range of tumour sites. Variations in the following LET calculation methods were considered: (i) averaging (dose-averaged LET (LETd) & track-averaged LET); (ii) scoring (LETdto water, to medium and to mass density); (iii) particle inclusion (LETdto all protons, to primary protons and to particles); (iv) MC settings (hit type and Maximum Step Size (MSS)). LET distributions were compared using: qualitative comparison, LET Volume Histograms (LVHs), single value criteria (maximum and mean values) and optimised LET-weighted dose models. Substantial differences were found between LET values in averaging, scoring and particle type. These differences depended on the methodology, but for one patient a difference of ∼100% was observed between the maximum LETdfor all particles and maximum LETdfor all protons within the brainstem in the high isodose region (4 keVµm-1and 8 keVµm-1respectively). An RBE model using LETdincluding heavier ions was found to predict substantially different LET-weighted dose compared to those using other LET definitions. In conclusion, the selection of LET definition may affect the results of clinical metrics considered in treatment planning and the results of an RBE model. The authors' advocate for the scoring of dose-averaged LET to water for primary and secondary protons using a random hit type and automated MSS.

Evaluation of GATE-RTion (GATE/Geant4) Monte Carlo simulation settings for proton pencil beam scanning quality assurance.

PURPOSE: Geant4 is a multi-purpose Monte Carlo simulation tool for modeling particle transport in matter. It provides a wide range of settings, which the user may optimize for their specific application. This study investigates GATE/Geant4 parameter settings for proton pencil beam scanning therapy. METHODS: GATE8.1/Geant4.10.3.p03 (matching the versions used in GATE-RTion1.0) simulations were performed with a set of prebuilt Geant4 physics lists (QGSP_BIC, QGSP_BIC_EMY, QGSP_BIC_EMZ, QGSP_BIC_HP_EMZ), using 0.1mm-10mm as production cuts on secondary particles (electrons, photons, positrons) and varying the maximum step size of protons (0.1mm, 1mm, none). The results of the simulations were compared to measurement data taken during clinical patient specific quality assurance at The Christie NHS Foundation Trust pencil beam scanning proton therapy facility. Additionally, the influence of simulation settings was quantified in a realistic patient anatomy based on computer tomography (CT) scans. RESULTS: When comparing the different physics lists, only the results (ranges in water) obtained with QGSP_BIC (G4EMStandardPhysics_Option0) depend on the maximum step size. There is clinically negligible difference in the target region when using High Precision neutron models (HP) for dose calculations. The EMZ electromagnetic constructor provides a closer agreement (within 0.35 mm) to measured beam sizes in air, but yields up to 20% longer execution times compared to the EMY electromagnetic constructor (maximum beam size difference 0.79 mm). The impact of this on patient-specific quality assurance simulations is clinically negligible, with a 97% average 2%/2 mm gamma pass rate for both physics lists. However, when considering the CT-based patient model, dose deviations up to 2.4% are observed. Production cuts do not substantially influence dosimetric results in solid water, but lead to dose differences of up to 4.1% in the patient CT. Small (compared to voxel size) production cuts increase execution times by factors of 5 (solid water) and 2 (patient CT). CONCLUSIONS: Taking both efficiency and dose accuracy into account and considering voxel sizes with 2 mm linear size, the authors recommend the following Geant4 settings to simulate patient specific quality assurance measurements: No step limiter on proton tracks; production cuts of 1 mm for electrons, photons and positrons (in the phantom and range-shifter) and 10 mm (world); best agreement to measurement data was found for QGSP_BIC_EMZ reference physics list at the cost of 20% increased execution times compared to QGSP_BIC_EMY. For simulations considering the patient CT model, the following settings are recommended: No step limiter on proton tracks; production cuts of 1 mm for electrons, photons and positrons (phantom/range-shifter) and 10 mm (world) if the goal is to achieve sufficient dosimetric accuracy to ensure that a plan is clinically safe; or 0.1 mm (phantom/range-shifter) and 1 mm (world) if higher dosimetric accuracy is needed (increasing execution times by a factor of 2); most accurate results expected for QGSP_BIC_EMZ reference physics list, at the cost of 10-20% increased execution times compared to QGSP_BIC_EMY.

Automated Monte-Carlo re-calculation of proton therapy plans using Geant4/Gate: implementation and comparison to plan-specific quality assurance measurements.

OBJECTIVES: Software re-calculation of proton pencil beam scanning plans provides a method of verifying treatment planning system (TPS) dose calculations prior to patient treatment. This study describes the implementation of AutoMC, a Geant4 v10.3.3/Gate v8.1 (Gate-RTion v1.0)-based Monte-Carlo (MC) system for automated plan re-calculation, and presents verification results for 153 patients (730 fields) planned within year one of the proton service at The Christie NHS Foundation Trust. METHODS: A MC beam model for a Varian ProBeam delivery system with four range-shifter options (none, 2 cm, 3 cm, 5 cm) was derived from beam commissioning data and implemented in AutoMC. MC and TPS (Varian Eclipse v13.7) calculations of 730 fields in solid-water were compared to physical plan-specific quality assurance (PSQA) measurements acquired using a PTW Octavius 1500XDR array and PTW 31021 Semiflex 3D ion chamber. RESULTS: TPS and MC showed good agreement with array measurements, evaluated using γ analyses at 3%, 3 mm with a 10% lower dose threshold:>94% of fields calculated by the TPS and >99% of fields calculated by MC had γ ≤ 1 for>95% of measurement points within the plane. TPS and MC also showed good agreement with chamber measurements of absolute dose, with systematic differences of <1.5% for all range-shifter options. CONCLUSIONS: Reliable independent verification of the TPS dose calculation is a valuable complement to physical PSQA and may facilitate reduction of the physical PSQA workload alongside a thorough delivery system quality assurance programme. ADVANCES IN KNOWLEDGE: A Gate/Geant4-based MC system is thoroughly validated against an extensive physical PSQA dataset for 730 clinical fields, showing that clinical implementation of MC for PSQA is feasible.

Pitfalls in the beam modelling process of Monte Carlo calculations for proton pencil beam scanning.

OBJECTIVE: Monte Carlo (MC) simulations substantially improve the accuracy of predicted doses. This study aims to determine and quantify the uncertainties of setting up such a MC system. METHODS: Doses simulated with two Geant4-based MC calculation codes, but independently tuned to the same beam data, have been compared. Different methods of MC modelling of a pre-absorber have been employed, either modifying the beam source parameters (descriptive) or adding the pre-absorber as a physical component (physical). RESULTS: After the independent beam modelling of both systems in water (resulting in excellent range agreement) range differences of up to 3.6/4.8 mm (1.5% of total range) in bone/brain-like tissues were found, which resulted from the use of different mean water ionisation potentials during the energy tuning process. When repeating using a common definition of water, ranges in bone/brain agreed within 0.1 mm and gamma-analysis (global 1%,1mm) showed excellent agreement (>93%) for all patient fields. However, due to a lack of modelling of proton fluence loss in the descriptive pre-absorber, differences of 7% in absolute dose between the pre-absorber definitions were found. CONCLUSION: This study quantifies the influence of using different water ionisation potentials during the MC beam modelling process. Furthermore, when using a descriptive pre-absorber model, additional Faraday cup or ionisation chamber measurements with pre-absorber are necessary. ADVANCES IN KNOWLEDGE: This is the first study quantifying the uncertainties caused by the MC beam modelling process for proton pencil beam scanning, and a more detailed beam modelling process for MC simulations is proposed to minimise the influence of critical parameters.

Preclinical dosimetry: exploring the use of small animal phantoms.

Preclinical radiotherapy studies using small animals are an indispensable step in the pathway from in vitro experiments to clinical implementation. As radiotherapy techniques advance in the clinic, it is important that preclinical models evolve to keep in line with these developments. The use of orthotopic tumour sites, the development of tissue-equivalent mice phantoms and the recent introduction of image-guided small animal radiation research platforms has enabled similar precision treatments to be delivered in the laboratory.These technological developments, however, are hindered by a lack of corresponding dosimetry standards and poor reporting of methodologies. Without robust and well documented preclinical radiotherapy quality assurance processes, it is not possible to ensure the accuracy and repeatability of dose measurements between laboratories. As a consequence current RT-based preclinical models are at risk of becoming irrelevant.In this review we explore current standardization initiatives, focusing in particular on recent developments in small animal irradiation equipment, 3D printing technology to create customisable tissue-equivalent dosimetry phantoms and combining these phantoms with commonly used detectors.

A robust optimisation approach accounting for the effect of fractionation on setup uncertainties.

Proton plans are subject to a number of uncertainties which must be accounted for to ensure that they are delivered safely. Misalignment resulting from residual errors in daily patient positioning can result in both a displacement and distortion of dose distributions. This can be particularly important for intensity modulated proton therapy treatments where the accurate alignment of highly modulated fields may be required to deliver the intended treatment. A number of methods to generate plans that are robust to these uncertainties exist. These include robust optimisation approaches which account for the effect of uncertainties on the dose distribution within the optimisation process. However, robustness to uncertainty comes at the cost of plan quality. For this reason, it is important that the uncertainties considered are realistic. Existing approaches to robust optimisation have neglected the role of fractionated treatment deliveries in reducing the uncertainties that result from random setup errors. Here, a method of robust optimisation which accounts for this effect is presented and is evaluated using a 2D planning environment. The optimisation algorithm considers the dose in the estimated upper and lower bounds of the dose distribution under the effect of setup and range errors. A comparison with plans robustly optimised without consideration of the effect of fractionation and conventionally optimised plans is presented. Fractionation incorporated robust optimisation demonstrates a reduced sensitivity to uncertainty compared to conventionally optimised plans and a reduced integral dose compared to robustly optimised plans.

The suitability of common metrics for assessing parotid and larynx autosegmentation accuracy.

Contouring structures in the head and neck is time-consuming, and automatic seg-mentation is an important part of an adaptive radiotherapy workflow. Geometric accuracy of automatic segmentation algorithms has been widely reported, but there is no consensus as to which metrics provide clinically meaningful results. This study investigated whether geometric accuracy (as quantified by several commonly used metrics) was associated with dosimetric differences for the parotid and larynx, comparing automatically generated contours against manually drawn ground truth contours. This enabled the suitability of different commonly used metrics to be assessed for measuring automatic segmentation accuracy of the parotid and larynx. Parotid and larynx structures for 10 head and neck patients were outlined by five clinicians to create ground truth structures. An automatic segmentation algorithm was used to create automatically generated normal structures, which were then used to create volumetric-modulated arc therapy plans. The mean doses to the automatically generated structures were compared with those of the corresponding ground truth structures, and the relative difference in mean dose was calculated for each structure. It was found that this difference did not correlate with the geometric accuracy provided by several metrics, notably the Dice similarity coefficient, which is a commonly used measure of spatial overlap. Surface-based metrics provided stronger correlation and are, therefore, more suitable for assessing automatic seg-mentation of the parotid and larynx.

A Monte Carlo study on the collimation of pencil beam scanning proton therapy beams.

PURPOSE: The lateral edge of a proton therapy beam is commonly used to achieve conformality to the treatment volume where critical structures reside close to the target. However, when treating shallow depths, the lateral edge of a pencil beam scanning (PBS) system may be broader than that of a double scattered (DS) system. Use of a range-shifter to degrade the beam and allow treatment of very shallow depths further blurs the lateral edge. The authors investigate the potential use of a collimator with a PBS system for delivery of 3D uniform dose-volumes to a water-tank phantom, identifying the key factors controlling the width of the lateral edge. METHODS: The geant4 application for tomographic emission (gate) Monte Carlo (MC) environment was used, following validation against previously published data. Key parameters for PBS beams were investigated to assess their impact on the lateral edge of both monoenergetic beams and uniform dose-volumes. These parameters included nozzle-to-surface distance (NSD), vacuum window-to-surface distance (VSD), use of a range-shifter, and spot optimization parameters. RESULTS: The lateral edge of an uncollimated PBS beam is particularly sensitive to VSD and NSD. While use of a range-shifter blurs the lateral edge, collimation allows the edge to be sharpened to between 2 and 4 mm depending on the depth of the target. Optimization of the spot weightings alone can provide a penumbral width close to that of a single spot, but also leads to poorer uniformity near the edge of the target volume. CONCLUSIONS: Collimation of PBS beams should be considered for superficial targets particularly for beams delivered through a range-shifter, since the resultant sharpening of the lateral edge will allow improved sparing of adjacent normal tissues. Further work is needed to develop collimators which are integrated into both nozzle designs and planning system optimization algorithms.

Incorporating the effect of fractionation in the evaluation of proton plan robustness to setup errors.

To ensure the safe delivery of proton therapy treatments it is important to evaluate the effect of potential uncertainties, such as patient mispositioning, on the intended dose distribution. However, it can be expected that the uncertainty resulting from patient positioning is reduced in a fractionated treatment due to the convergence of random variables with the delivery of repeated treatments. This is neglected by current approaches to robustness analysis resulting in an overly conservative assessment of the robustness which can lead to sub-optimal plans. Here, a fast method of accounting for this reduced uncertainty is presented. An estimated bound to the error in the dose distribution resulting from setup uncertainty over a specified number of fractions is calculated by considering the distribution of values for each voxel across 14 initial error scenarios. The bound on the error in a given voxel is estimated using a 99.9% confidence limit assuming a convergence towards a normal distribution in line with the central limit theorem, and a correction of [Formula: see text] accounting for the reduction in the standard deviation over n fractions. The proposed method was validated in 5 patients by comparison to Monte Carlo simulations of 300 treatment courses. A voxelwise and volumetric analysis of the estimated and simulated bounds to the uncertainty in the dose distribution demonstrate that the proposed technique can be used to assess proton plan robustness more accurately allowing for less conservative treatment plans.

Parametrized rectal dose and associations with late toxicity in prostate cancer radiotherapy.

OBJECTIVE: We investigated possible associations between planned dose-volume parameters and rectal late toxicity in 170 patients having radical prostate cancer radiotherapy. METHODS: For each patient, the rectum was outlined from anorectal junction to sigmoid colon, and rectal dose was parametrized using dose-volume (DVH), dose-surface (DSH) and dose-line (DLH) histograms. Generation of DLHs differed from previous studies in that the rectal dose was parametrized without first unwrapping onto 2-dimensional dose-surface maps. Patient-reported outcomes were collected using a validated Later Effects in Normal Tissues Subjective, Objective, Management and Analytic questionnaire. Associations between dose and toxicity were assessed using a one-sided Mann-Whitney U test. RESULTS: Associations (p < 0.05) were found between equieffective dose (EQD23) and late toxicity as follows: overall toxicity with DVH and DSH at 13-24 Gy; proctitis with DVH and DSH at 25-36 Gy and with DVH, DSH and DLH at 61-67 Gy; bowel urgency with DVH and DSH at 10-20 Gy. None of these associations met statistical significance following the application of a Bonferroni correction. CONCLUSION: Independently confirmed associations between rectal dose and late toxicity remain elusive. Future work to increase the accuracy of the knowledge of the rectal dose, either by accounting for interfraction and intrafraction rectal motion or via stabilization of the rectum during treatment, may be necessary to allow for improved dose-toxicity comparisons. ADVANCES IN KNOWLEDGE: This study is the first to use parametrized DLHs to study associations with patient-reported toxicity for prostate radiotherapy showing that it is feasible to model rectal dose mapping in three dimensions.

Evaluation of an automatic segmentation algorithm for definition of head and neck organs at risk.

BACKGROUND: The accurate definition of organs at risk (OARs) is required to fully exploit the benefits of intensity-modulated radiotherapy (IMRT) for head and neck cancer. However, manual delineation is time-consuming and there is considerable inter-observer variability. This is pertinent as function-sparing and adaptive IMRT have increased the number and frequency of delineation of OARs. We evaluated accuracy and potential time-saving of Smart Probabilistic Image Contouring Engine (SPICE) automatic segmentation to define OARs for salivary-, swallowing- and cochlea-sparing IMRT. METHODS: Five clinicians recorded the time to delineate five organs at risk (parotid glands, submandibular glands, larynx, pharyngeal constrictor muscles and cochleae) for each of 10 CT scans. SPICE was then used to define these structures. The acceptability of SPICE contours was initially determined by visual inspection and the total time to modify them recorded per scan. The Simultaneous Truth and Performance Level Estimation (STAPLE) algorithm created a reference standard from all clinician contours. Clinician, SPICE and modified contours were compared against STAPLE by the Dice similarity coefficient (DSC) and mean/maximum distance to agreement (DTA). RESULTS: For all investigated structures, SPICE contours were less accurate than manual contours. However, for parotid/submandibular glands they were acceptable (median DSC: 0.79/0.80; mean, maximum DTA: 1.5 mm, 14.8 mm/0.6 mm, 5.7 mm). Modified SPICE contours were also less accurate than manual contours. The utilisation of SPICE did not result in time-saving/improve efficiency. CONCLUSIONS: Improvements in accuracy of automatic segmentation for head and neck OARs would be worthwhile and are required before its routine clinical implementation.

Simulation of realistic linac motion improves the accuracy of a Monte Carlo based VMAT plan QA system.

PURPOSE: To investigate the use of a software-based pre-treatment QA system for VMAT, which incorporates realistic linac motion during delivery. METHODS: A beam model was produced using the GATE platform for GEANT4 Monte Carlo dose calculations. Initially validated against static measurements, the model was then integrated with a VMAT delivery emulator, which reads plan files and generates a set of dynamic delivery instructions analogous to the linac control system. Monte Carlo simulations were compared to measurements on dosimetric phantoms for prostate and head and neck VMAT plans. Comparisons were made between calculations using fixed control points, and simulations of continuous motion utilising the emulator. For routine use, the model was incorporated into an automated pre-treatment QA system. RESULTS: The model showed better agreement with measurements when incorporating linac motion: mean gamma pass (Γ<1) over 5 prostate plans was 100.0% at 3%/3mm and 97.4% at 2%/2mm when compared to measurement. For the head and neck plans, delivered to the anatomical phantom, gamma passes were 99.4% at 4%/4mm and 94.94% at 3%/3mm. For example simulations within patient CT data, gamma passes were observed which are within our centre's tolerance for pre-treatment QA. CONCLUSIONS: Through comparison to phantom measurements, it was found that the incorporation of a realistic linac motion improves the accuracy of the model compared to the simulation of fixed control points. The ability to accurately calculate dose as a second check of the planning system, and determine realistic delivery characteristics, may allow for the reduction of machine-based pre-treatment plan QA for VMAT.

An analysis of the origin of differences between measured and simulated fields produced by a 15-element ultrasound phased array.

Modeling provides an attractive approach for the design of phased array ultrasound transducers for hyperthermia. However, measurements on physical transducers reveal differences from the idealized field profiles predicted by simulation. In this paper we report a method of analyzing the origins of these differences. The measured performance of a 15-element sparse phased array is described and compared with simulated fields calculated using the point source method. It highlighted two notable differences: First, that the focal region was located closer to the surface of the physical transducer than in the simulated fields; and second, that numerous intensity maxima were present between the surface of the transducer and the focal zone in the experimental data, but not in the simulated fields. We identified six factors that could potentially affect the field but were not taken into account by the default simulations, and we performed a sensitivity analysis on these: (i) Variation in the amplitude of the output from each element, (ii) the presence of square-wave harmonics in the drive signals, (iii) nonpistonlike vibration of elements, (iv) quantization of the applied phases, (v) errors in the spatial positioning of each element; and (vi) interelement cross-coupling. Both the independent impact of each factor and the interactions between multiple factors were analyzed by using a full-factorial experimental design composed of 64 (2(6)) simulations. The results indicated that nonpistonlike motion of elements is likely to be the primary cause of differences between the measured and modelled fields. Determination of the precise vibrational modes of elements in an array is complex and would require full finite element analysis. However, the simple vibrational mode considered within the present work, corresponding to the addition of a surface Rayleigh wave originating at the element center and propagating radially, produced simulation results that were in good agreement with the measured data.

The design and characterization of an ultrasound phased array suitable for deep tissue hyperthermia.

In this paper we describe the design and evaluation of a planar phased-array ultrasound transducer suitable for producing localized hyperthermia in solid tumors deep within the body. Simulation using a customized version of Ultrasim has been used to determine the relationship between the size and position of the focus and parameters of the array. These parameters include the overall size of the array and the size, shape and distribution of the individual elements. A 15-element prototype array has been constructed using the results of the simulation. Beam profile measurements on this transducer made in an acoustic tank were compared with the beam profile predicted by simulation. The results showed good agreement in the shape of the focal region, but with the focus closer to the surface of the physical transducer when compared with the simulation and with small high-intensity areas between the surface of the transducer and the focus in the measured profile. A sensitivity analysis using a simulated factorial experiment indicated that the presence of a secondary vibrational mode within the elements of the array was the principal cause for both the shift in the position of the focus and for the unwanted maxima close to the surface of the array. The results also showed that the array was tolerant of a large variation in output intensity of the individual elements in the array in producing a focal region. Extrapolation of the results obtained in this study indicate that an array of 60 elements, based on the design described, driven by 550 V peak-to-peak pulses would be capable of producing a peak focal intensity of 50 Wcm(-2) at a depth of 60 mm in tissue, which would be appropriate for hyperthermia used as an adjunct to radiotherapy or chemotherapy.